Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase 1 Pharmacokinetic and Tolerability Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01645930
• Other study ID #: C16013
• Secondary ID: U1111-1155-5943H
• Status: Completed
• Phase: Phase 1
• Start date: December 17, 2012
• Est. completion date: April 11, 2017

Study information

• Verified date: March 2018
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this Phase 1 study is to characterize the pharmacokinetic (PK) and tolerability of oral ixazomib (MLN9708) when administered in combination with lenalidomide and dexamethasone in adult Asian participants with relapsed and/or refractory multiple myeloma.

Description:

The drug being tested in this study was ixazomib. Ixazomib was tested to treat adult Asian people who had relapsed and/or refractory multiple myeloma.

The study enrolled 43 patients. Participants were enrolled to receive:

• Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg.

All participants were asked to take ixazomib capsules orally on Days 1, 8, and 15; lenalidomide capsules, orally, on Days 1 through 21; and dexamethasone tablets, orally, on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles).

This multi-center trial was conducted in Singapore, Hong Kong and South Korea. The overall time to participate in this study was up to 577 days. Participants made multiple visits to the clinic, and were contacted 30 days after last dose of study drug for a follow-up assessment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: April 11, 2017
• Est. primary completion date: July 14, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female East Asian participants 18 years or older

• Diagnosed Multiple Myeloma according to standard criteria

• Measurable disease as specified in study protocol

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

• Participants with relapsed and/or refractory Multiple Myeloma who have received 1 to 3 prior therapies

• Meet the clinical laboratories criteria as specified in the protocol

• Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse; must also adhere to the guidelines of the lenalidomide pregnancy prevention program

• Male participants who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse and must adhere to the guidelines of the lenalidomide pregnancy prevention program

• Must be able to take concurrent aspirin 325 mg daily

• Voluntary written consent

Exclusion Criteria:

• Female participants who are lactating or pregnant

• Major surgery or radiotherapy within 14 days before enrollment

• Infection requiring systematic antibiotics within 14 days before study enrollment

• Central nervous system involvement

• Failure to have fully recovered from the effects of prior chemotherapy regardless of the interval since last treatment

• Systemic treatment with strong inhibitors of cytochrome P450 1A2 (CYP1A2), strong inhibitors of CYP3A, or strong CYP3A inducers, or use of Ginko biloba or St. John's wort within 14 days before study enrollment

• Diagnosis of Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome

• Evidence of current uncontrolled cardiovascular conditions

• Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol

• Known allergy to any of the study medications

• Known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption of tolerance of ixazomib

• Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situ

• Ongoing or active systemic infection, active hepatitis B virus infect, active hepatitis C infection, or known human immunodeficiency virus (HIV) positive

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Ixazomib
Ixazomib capsules
• Lenalidomide
Lenalidomide capsules
• Dexamethasone
Dexamethasone tablets

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Millennium Pharmaceuticals, Inc.

Countries where clinical trial is conducted

Hong Kong,  Korea, Republic of,  Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax: Maximum Observed Plasma Concentration for Ixazomib		Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
Primary	Cmax: Maximum Observed Plasma Concentration for Ixazomib		Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
Primary	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib		Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
Primary	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib		Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
Primary	AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Ixazomib		Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
Primary	AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Ixazomib		Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
Primary	Number of Participants With Dose Limiting Toxicities (DLTs)	DLT was defined as any of the following AEs that were considered by investigator to be possibly related to therapy: 1. Grade 4 neutropenia lasting at least 7 consecutive days; 2. Grade 3 neutropenia with fever and/or infection; 3. Grade 4 thrombocytopenia at least 7 consecutive days; 4. Grade 3 thrombocytopenia with clinically significant bleeding; 5. Platelet count <10,000/mm^3; 6. Grade 2 peripheral neuropathy with pain or =Grade 3 peripheral neuropathy; 7. Grade 3 or greater nausea and / or emesis despite the use of optimal anti-emetic prophylaxis; 8. Grade 3 or greater diarrhea that occurred despite maximal supportive therapy; 9. Any other Grade 3 or greater nonhematologic toxicity with the following exceptions: Grade 3 arthralgia/myalgia, <1 week Grade 3 fatigue; 10. A delay of >2 weeks in the subsequent cycle of treatment; 11. Other combination study drug-related nonhematologic toxicities =Grade 2 that, in the opinion of the investigator, required discontinuation of study drug.	Cycle 1 (up to Day 28)
Primary	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or was a medically important event.	From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
Primary	Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Adverse Events of =Grade 3 Intensity	Clinically significant laboratory abnormalities were defined as any test results which were observed beyond the clinically acceptable limits as per the discretion of investigator. Clinical laboratory tests included chemistry, hematology and urinalysis tests.	From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
Primary	Number of Participants With Clinically Significant Vital Signs Reported as Adverse Events	The number of participants who meet markedly abnormal criteria for vital signs, included diastolic and systolic blood pressure, heart rate, oral temperature, respiratory rate, and body weight.	From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
Secondary	Percentage of Participants With Confirmed Best Response Category	Percentage of participants who achieve or maintain any best response category during the treatment period were reported. Best response includes complete response (CR), very good partial response (VGPR), and partial response (PR). Response was assessed according to IMWG criteria. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and =5% plasma cells in bone marrow; PR: =50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by =90% or to <200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or =90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 hour.	From Cycle 1, Day 1 to Cycle 3, Day 1 until disease progression (approximately 20 months)
Secondary	Duration of Response (DOR)	DOR was defined as the length of time between the date of first documented response (PR, VGPR, or CR) and the date of first documented progressive disease (PD). According to IMWG criteria: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and =5% plasma cells in bone marrow; PR: =50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by =90% or to <200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or =90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 hour.	From date of documentation of a confirmed response to date of progressive disease, (approximately 20 months)